Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States

Our purpose was to evaluate the effect of PD-L1 testing on the cost-effectiveness of pembrolizumab for second-line treatment of advanced urothelial carcinoma in the bladder from the U.S. societal perspective. We developed a microsimulation model to compare 3 treatment strategies: (1) treat all patie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Urologic oncology 2019-03, Vol.37 (3), p.180.e11-180.e18
Hauptverfasser:	Criss, Steven D., Weaver, Davis T., Sheehan, Deirdre F., Lee, Richard J., Pandharipande, Pari V., Kong, Chung Yin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - economics Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use B7-H1 Antigen - analysis B7-H1 Antigen - metabolism Bladder cancer Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - economics Carcinoma, Transitional Cell - mortality Computer Simulation Cost-Benefit Analysis Cost-effectiveness analysis Drug Costs Humans Immunotherapy Models, Economic Patient Selection Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - metabolism Progression-Free Survival Quality-Adjusted Life Years United States Urinary Bladder - pathology Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - economics Urinary Bladder Neoplasms - mortality Urothelial carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!